3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
55
Recurrence
7
Lymphoma
6
Neoplasms, Plasma Cell
5
Immunoglobulin Light-chain Amyloidosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
beta-Thalassemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphadenopathy
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Nivolumab
3
tivozanib
1
regorafenib
1
neratinib
1
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
capivasertib
1
Valproic Acid
1
Thioctic Acid
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Gemcitabine
1
Fulvestrant
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Bortezomib
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Bortezomib
×
90 days
×
Clear all
NCT01191060
2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3
Completed
700 enrolled